Kartal

Nimesulide, the active ingredient in Kartal, is a non‑steroidal anti‑inflammatory drug (NSAID) presented as an oral tablet for systemic use. It is employed to relieve pain, reduce fever, and diminish inflammation in adult patients requiring short‑term symptom control. The medication is marketed in the European Union and requires a prescription.\n\nGNH India supplies Kartal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nimesulide is an NSAID that reduces inflammation and pain by inhibiting the cyclooxygenase‑2 enzyme.\n\nAcute pain: provides short‑term analgesic relief for conditions such as dental pain, postoperative discomfort, or musculoskeletal aches.\nFever: lowers elevated body temperature associated with infections or inflammatory processes.\nInflammatory conditions: diminishes swelling and discomfort in disorders like bursitis or tendonitis.

Nimesulide may cause a range of adverse reactions, which are categorized by frequency and severity.\n\nCommon Side Effects:\n- Gastrointestinal discomfort: nausea, dyspepsia, or abdominal pain.\n- Headache: mild to moderate intensity.\n- Dizziness: transient sensation of light‑headedness.\n- Rash: mild skin irritation or itching.\n\nSerious or Rare Side Effects:\n- Hepatotoxicity: elevated liver enzymes or severe liver injury.\n- Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.\n- Renal impairment: reduced kidney function or acute renal failure.\n- Anaphylaxis: life‑threatening allergic reaction with airway compromise.

Before prescribing Nimesulide, clinicians should consider several safety precautions to minimize risk.\n\nAssess liver function: obtain baseline hepatic enzymes and monitor periodically during treatment.\nEvaluate renal status: check kidney function especially in patients with pre‑existing impairment.\nUse lowest effective dose: limit duration to the shortest period required for symptom control.\nAvoid in patients with known hypersensitivity to NSAIDs or sulfonamides.\nConcurrent anticoagulant therapy: monitor bleeding risk closely.\nStore at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Nimesulide can interact with other medicines, and some combinations should be avoided or closely monitored.\n\nMajor Interactions (Avoid):\n- Anticoagulants (e.g., warfarin): increased risk of bleeding.\n- Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity.\n- Lithium: elevated lithium levels leading to toxicity.\n\nModerate Interactions (Monitor Closely):\n- Methotrexate: reduced clearance may enhance toxicity.\n- ACE inhibitors or diuretics: possible reduction in antihypertensive effect and renal function.